Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

NCT ID: NCT00974610

Last Updated: 2017-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

803 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.

Secondary

* To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Colorectal Cancer Lung Cancer Melanoma (Skin) Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast

No interventions assigned to this group

Lung

No interventions assigned to this group

Melanoma

No interventions assigned to this group

Pancreatic

No interventions assigned to this group

Colorectal

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following advanced metastatic malignancies:

* Malignant melanoma
* Lung cancer
* Breast cancer
* Pancreatic carcinoma
* Colorectal cancer
* Advanced and/or metastatic disease
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Menopausal status not specified

PRIOR CONCURRENT THERAPY:

* Not specified
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cancer Trials Ireland

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Clynes

Role: PRINCIPAL_INVESTIGATOR

National Institute for Cellular Biotechnology at Dublin City University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cork University Hospital

Cork, , Ireland

Site Status

Mercy University Hospital

Cork, , Ireland

Site Status

Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital

Dublin, , Ireland

Site Status

St. Vincent's University Hospital

Dublin, , Ireland

Site Status

Mater Misericordiae University Hospital

Dublin, , Ireland

Site Status

St. James's Hospital

Dublin, , Ireland

Site Status

Beaumont Hospital

Dublin, , Ireland

Site Status

Mater Private Hospital

Dublin, , Ireland

Site Status

St Luke's Hospital

Dublin, , Ireland

Site Status

University College Hospital

Galway, , Ireland

Site Status

Letterkenny General Hospital

Letterkenny, , Ireland

Site Status

Mid-Western Cancer Centre at Mid-Western Regional Hospital

Limerick, , Ireland

Site Status

Waterford Regional Hospital

Waterford, , Ireland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Ireland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTRIAL-IE (ICORG) 07-12

Identifier Type: -

Identifier Source: secondary_id

EU-20949

Identifier Type: -

Identifier Source: secondary_id

CTRIAL-IE (ICORG) 07-12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.